NYSE:PFEPharmaceuticals
Should Pfizer’s (PFE) New 25‑Valent Vaccine Data and Oncology Alliance Require Action From Investors?
In May 2026, Sarah Cannon Research Institute announced a collaboration with Pfizer to accelerate development of Pfizer’s oncology portfolio using SCRI’s Accelero clinical trial model, while Pfizer also reported strong Phase 2 data for its 25-valent pneumococcal vaccine candidate in infants compared with Prevnar 20 and moved it into pivotal Phase 3 trials.
A particularly important insight is 25vPnC’s much stronger immune response against serotype 3, a persistent driver of serious pediatric...